RS58813B1 - Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret) - Google Patents
Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret)Info
- Publication number
- RS58813B1 RS58813B1 RS20190559A RSP20190559A RS58813B1 RS 58813 B1 RS58813 B1 RS 58813B1 RS 20190559 A RS20190559 A RS 20190559A RS P20190559 A RSP20190559 A RS P20190559A RS 58813 B1 RS58813 B1 RS 58813B1
- Authority
- RS
- Serbia
- Prior art keywords
- ret
- kinase inhibitors
- during transfection
- pyridone derivatives
- rearranged during
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014086197 | 2014-09-10 | ||
| CN2015086995 | 2015-08-14 | ||
| PCT/IB2015/056905 WO2016038552A1 (en) | 2014-09-10 | 2015-09-09 | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors |
| EP15767599.2A EP3191450B1 (en) | 2014-09-10 | 2015-09-09 | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS58813B1 true RS58813B1 (sr) | 2019-07-31 |
Family
ID=54186249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20190559A RS58813B1 (sr) | 2014-09-10 | 2015-09-09 | Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret) |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US9918974B2 (sr) |
| EP (2) | EP3191450B1 (sr) |
| JP (2) | JP6538154B2 (sr) |
| KR (1) | KR20170045350A (sr) |
| CN (1) | CN107074768B (sr) |
| AU (1) | AU2015313841B2 (sr) |
| BR (1) | BR112017004900A2 (sr) |
| CA (1) | CA2960768A1 (sr) |
| CL (1) | CL2017000588A1 (sr) |
| CO (1) | CO2017002273A2 (sr) |
| CR (1) | CR20170093A (sr) |
| CY (1) | CY1121661T1 (sr) |
| DK (1) | DK3191450T3 (sr) |
| DO (1) | DOP2017000059A (sr) |
| EA (1) | EA033544B1 (sr) |
| ES (2) | ES2816453T3 (sr) |
| HR (1) | HRP20190815T1 (sr) |
| HU (1) | HUE044604T2 (sr) |
| IL (1) | IL250908B (sr) |
| LT (1) | LT3191450T (sr) |
| MA (1) | MA40581A (sr) |
| ME (1) | ME03432B (sr) |
| MX (1) | MX2017003114A (sr) |
| MY (1) | MY181913A (sr) |
| PE (1) | PE20170705A1 (sr) |
| PH (1) | PH12017500425B1 (sr) |
| PL (1) | PL3191450T3 (sr) |
| PT (1) | PT3191450T (sr) |
| RS (1) | RS58813B1 (sr) |
| SG (1) | SG11201701694QA (sr) |
| SI (1) | SI3191450T1 (sr) |
| TW (1) | TWI683807B (sr) |
| UA (1) | UA122213C2 (sr) |
| UY (1) | UY36293A (sr) |
| WO (1) | WO2016038552A1 (sr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3205654T3 (pl) | 2010-05-20 | 2019-08-30 | Array Biopharma, Inc. | Związki makrocykliczne jako inhibitory kinazy TRK |
| DK3191449T3 (da) | 2014-09-10 | 2020-08-03 | Glaxosmithkline Ip Dev Ltd | Forbindelser som ret- (rearranged during transfection) hæmmere |
| US9918974B2 (en) | 2014-09-10 | 2018-03-20 | Glaxosmithkline Intellectual Property Development Limited | Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| EP4292594A3 (en) | 2015-11-02 | 2024-03-27 | Blueprint Medicines Corporation | Inhibitors of ret |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018213329A1 (en) | 2017-05-15 | 2018-11-22 | Blueprint Medicines Corporation | Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| RS65127B1 (sr) | 2018-04-03 | 2024-02-29 | Blueprint Medicines Corp | Ret inhibitor za primenu u lečenju kancera koji ima ret alteraciju |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| TWI786742B (zh) * | 2020-07-23 | 2022-12-11 | 大陸商深圳晶泰科技有限公司 | 吡啶酮類化合物及其製備方法和應用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120046290A1 (en) | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
| MXPA00006233A (es) | 1997-12-22 | 2002-09-18 | Bayer Ag | Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas. |
| BR9814374B1 (pt) | 1997-12-22 | 2013-09-17 | "urÉias heterocÍclicas substituÍdas e composiÇÕes compreendendo as mesmas" | |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| KR20020060160A (ko) | 1999-08-12 | 2002-07-16 | 파마시아 이탈리아 에스.피.에이. | 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도 |
| CA2430151A1 (en) * | 2000-11-27 | 2002-06-20 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| WO2004024694A1 (ja) | 2002-09-10 | 2004-03-25 | Kyorin Pharmaceutical Co., Ltd. | ４-置換アリール-５-ヒドロキシイソキノリノン誘導体 |
| WO2005018624A2 (en) | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating copd and pulmonary hypertension |
| TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| WO2006071960A2 (en) * | 2004-12-28 | 2006-07-06 | Kinex Pharmaceuticals, Llc | Compositions and methods of treating cell proliferation disorders |
| GB0507575D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
| WO2008002676A2 (en) | 2006-06-29 | 2008-01-03 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| KR101507375B1 (ko) * | 2006-09-15 | 2015-04-07 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | 키나아제 억제제 화합물 |
| US7977338B2 (en) * | 2006-10-16 | 2011-07-12 | Novartis Ag | Phenylacetamides being FLT3 inhibitors |
| EP2099774A4 (en) | 2006-11-15 | 2010-11-24 | Ym Biosciences Australia Pty L | INHIBITORS OF KINASEACTIVITY |
| US20130035326A1 (en) | 2009-08-19 | 2013-02-07 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
| WO2012082817A1 (en) | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| EP2970191B1 (en) | 2013-03-15 | 2016-12-21 | GlaxoSmithKline Intellectual Property Development Limited | Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors |
| US8937071B2 (en) | 2013-03-15 | 2015-01-20 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
| US9918974B2 (en) | 2014-09-10 | 2018-03-20 | Glaxosmithkline Intellectual Property Development Limited | Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors |
| DK3191449T3 (da) | 2014-09-10 | 2020-08-03 | Glaxosmithkline Ip Dev Ltd | Forbindelser som ret- (rearranged during transfection) hæmmere |
-
2015
- 2015-09-09 US US15/509,613 patent/US9918974B2/en not_active Expired - Fee Related
- 2015-09-09 ME MEP-2019-136A patent/ME03432B/me unknown
- 2015-09-09 SI SI201530720T patent/SI3191450T1/sl unknown
- 2015-09-09 CN CN201580058320.5A patent/CN107074768B/zh not_active Expired - Fee Related
- 2015-09-09 PE PE2017000417A patent/PE20170705A1/es unknown
- 2015-09-09 SG SG11201701694QA patent/SG11201701694QA/en unknown
- 2015-09-09 ES ES19160650T patent/ES2816453T3/es active Active
- 2015-09-09 LT LTEP15767599.2T patent/LT3191450T/lt unknown
- 2015-09-09 CR CR20170093A patent/CR20170093A/es unknown
- 2015-09-09 DK DK15767599.2T patent/DK3191450T3/da active
- 2015-09-09 UA UAA201703478A patent/UA122213C2/uk unknown
- 2015-09-09 AU AU2015313841A patent/AU2015313841B2/en not_active Ceased
- 2015-09-09 EP EP15767599.2A patent/EP3191450B1/en active Active
- 2015-09-09 BR BR112017004900A patent/BR112017004900A2/pt not_active IP Right Cessation
- 2015-09-09 EP EP19160650.8A patent/EP3517526B1/en active Active
- 2015-09-09 PL PL15767599T patent/PL3191450T3/pl unknown
- 2015-09-09 ES ES15767599T patent/ES2725704T3/es active Active
- 2015-09-09 WO PCT/IB2015/056905 patent/WO2016038552A1/en active Application Filing
- 2015-09-09 CA CA2960768A patent/CA2960768A1/en not_active Abandoned
- 2015-09-09 RS RS20190559A patent/RS58813B1/sr unknown
- 2015-09-09 KR KR1020177009237A patent/KR20170045350A/ko not_active Application Discontinuation
- 2015-09-09 MY MYPI2017700782A patent/MY181913A/en unknown
- 2015-09-09 MA MA040581A patent/MA40581A/fr unknown
- 2015-09-09 HU HUE15767599 patent/HUE044604T2/hu unknown
- 2015-09-09 MX MX2017003114A patent/MX2017003114A/es active IP Right Grant
- 2015-09-09 PT PT15767599T patent/PT3191450T/pt unknown
- 2015-09-09 EA EA201790546A patent/EA033544B1/ru not_active IP Right Cessation
- 2015-09-09 JP JP2017513450A patent/JP6538154B2/ja not_active Expired - Fee Related
- 2015-09-10 UY UY0001036293A patent/UY36293A/es unknown
- 2015-09-10 TW TW104129876A patent/TWI683807B/zh not_active IP Right Cessation
-
2017
- 2017-03-02 IL IL250908A patent/IL250908B/en active IP Right Grant
- 2017-03-07 CO CONC2017/0002273A patent/CO2017002273A2/es unknown
- 2017-03-07 DO DO2017000059A patent/DOP2017000059A/es unknown
- 2017-03-07 PH PH12017500425A patent/PH12017500425B1/en unknown
- 2017-03-09 CL CL2017000588A patent/CL2017000588A1/es unknown
-
2018
- 2018-01-23 US US15/877,524 patent/US10111866B2/en not_active Expired - Fee Related
- 2018-09-28 US US16/145,271 patent/US10292975B2/en not_active Expired - Fee Related
-
2019
- 2019-04-05 US US16/376,858 patent/US10709695B2/en not_active Expired - Fee Related
- 2019-05-02 HR HRP20190815TT patent/HRP20190815T1/hr unknown
- 2019-05-09 CY CY20191100502T patent/CY1121661T1/el unknown
- 2019-05-31 JP JP2019102776A patent/JP6728447B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250908B (en) | Pyridone derivatives as ret kinase inhibitors | |
| IL250923B (en) | New compounds as ret inhibitors | |
| IL241161A0 (en) | History of pyridine as inhibitors of rearrangement during transfection (ret) kinases | |
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| EP3131900A4 (en) | Heterocyclic kinase inhibitors | |
| ZA201701841B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| HK1232227A1 (zh) | 作為 抑制劑的喹嗪酮衍生物 | |
| HK1253576A1 (zh) | 作為mnk抑制劑的吡咯並嘧啶化合物 | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
| IL248568B (en) | A process for the preparation of dihydroisoxazole derivatives | |
| PL2958531T3 (pl) | Metoda ustawiania parametrów impulsu laserowego związanych z energią | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| GB201416351D0 (en) | Heterocyclic derivatives | |
| ZA201506309B (en) | Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors | |
| TH1501005474A (th) | อนุพันธ์ไพริดีนในรูปสารยับยั้งไคเนสถูกจัดเรียงใหม่ในระหว่างการทรานส์เฟคชั่น (ret) | |
| GB201404570D0 (en) | Macrocyclic kinase inhibitors | |
| GB201404555D0 (en) | Macrocyclic kinase inhibitors |